In United Kingdom, sjogren Syndrome is managed by rheumatologists. Sjogren syndrome is a chronic autoimmune disease in which lymphocytes infiltrate and destroy the lacrimal and salivary glands, producing persistent dry eyes and dry mouth alongside systemic features that can involve joints, lungs, kidneys, blood vessels, and the nervous system. Global prevalence sits between 0.05 and 1 percent of adults, with women affected roughly 9 to 1 over men and a peak onset between ages 40 and 60.
Sjogren syndrome (ICD-10: M35.0, sicca syndrome) is a slowly progressive autoimmune exocrinopathy characterized by chronic lymphocytic infiltration of the lacrimal and salivary glands, leading to reduced tear and saliva production and a wide spectrum of extraglandular manifestations. The dominant immunologic features are autoantibodies against Ro/SSA (in 60-80 percent) and La/SSB (in 30-40 percent), polyclonal hypergammaglobulinemia, positive rheumatoid factor in around 60 percent, and a striking type I interferon signature. Histologically, focal lymphocytic sialadenitis with a focus score of at least 1 focus per 4 mm squared on labial salivary gland biopsy is the pathologic hallmark. Two clinical forms are recognized: primary Sjogren syndrome, in which the disease stands alone, and secondary Sjogren syndrome, which develops in the context of another connective tissue disease, most often rheumatoid arthritis, systemic lupus erythematosus, or systemic sclerosis.
The key symptoms of Sjogren Syndrome are: Persistent dry eyes with a gritty, sandy, or burning sensation that worsens through the day, made worse by wind, air conditioning, screens, and contact lenses, present in over 95 percent of patients., Dry mouth with difficulty swallowing dry foods such as bread or crackers without water, frequent need to sip fluids during meals, altered taste, and an increase in dental cavities at the gum line., Recurrent or persistent swelling of the parotid or submandibular glands, sometimes bilateral, lasting weeks to months and usually painless unless secondarily infected., Severe fatigue out of proportion to activity, reported by 70-80 percent of patients and often the most disabling symptom regardless of glandular severity., Inflammatory joint pain and morning stiffness in the hands, wrists, and knees that mimics rheumatoid arthritis but is non-erosive and rarely deforms joints., Vaginal dryness, dyspareunia, and recurrent yeast infections in women, plus dryness of skin, nose, and throat with frequent throat clearing and dry cough., Raynaud phenomenon with cold-triggered color change of the fingers, present in around one-third of patients and often pre-dating the sicca symptoms by years..
Sjogren syndrome is diagnosed by combining sicca symptoms, objective tests of tear and saliva production, autoantibodies, and either a confirmatory minor salivary gland biopsy or characteristic imaging. The 2016 ACR/EULAR classification criteria (Shiboski 2017) are now standard: eligibility requires at least one sicca symptom or ESSDAI item, then five weighted items are summed — focal lymphocytic sialadenitis with focus score at least 1 (3 points), anti-Ro/SSA positive (3 points), ocular staining score at least 5 in at least one eye (1 point), Schirmer test at most 5 mm in 5 minutes in at least one eye (1 point), and unstimulated whole salivary flow rate at most 0.1 mL per minute (1 point). A score of 4 or more classifies a patient as having Sjogren syndrome with high sensitivity and specificity (96 percent and 95 percent). The older 2002 American-European Consensus Group (AECG) criteria (Vitali 2002) remain widely used in older literature and require 4 of 6 items including either anti-Ro positivity or a positive minor salivary gland biopsy. Exclusion criteria are mandatory: prior head and neck radiation, active hepatitis C with positive PCR, AIDS, sarcoidosis, amyloidosis, graft-versus-host disease, IgG4-related disease, and anticholinergic drug use must all be ruled out because each can mimic Sjogren. Once classification is met, the workup characterizes disease activity (ESSDAI score), damage (ESSDDI), and screens for organ involvement: complete blood count for cytopenias, comprehensive metabolic panel and urinalysis for renal disease, immunoglobulins and serum protein electrophoresis for hypergammaglobulinemia or monoclonal gammopathy, cryoglobulins, complement (C3, C4), and chest imaging if respiratory symptoms are present. Rheumatology referral is appropriate whenever sicca symptoms are persistent or accompanied by extraglandular features, anti-Ro positivity, or unexplained hypergammaglobulinemia.
Overall survival in primary Sjogren syndrome is similar to the age- and sex-matched general population in patients without organ-threatening disease or lymphoma. The dominant long-term concern is B-cell non-Hodgkin lymphoma, which develops in approximately 5-10 percent of patients across a lifetime — a 5 to 20 fold elevation over baseline and the highest lymphoma risk of any systemic autoimmune disease. Risk is concentrated in patients with persistent parotid swelling, palpable purpura, cryoglobulinemia, low C4, lymphopenia, monoclonal gammopathy, and high ESSDAI scores; the EULAR-developed 7-item lymphoma predictor model stratifies risk over 5 and 10 years. Mortality is driven mostly by lymphoma, infections under immunosuppression, and cardiovascular disease. Sicca features tend to progress slowly over years rather than fluctuate; severe ocular surface disease, dental loss, and chronic fatigue dominate long-term quality of life. Modern care that combines aggressive sicca management, treat-to-target reduction in ESSDAI, judicious use of rituximab in systemic disease, and structured lymphoma surveillance has improved outcomes substantially over the past two decades.
A rheumatologist should lead long-term care from diagnosis onward. Specialist referral is essential when sicca symptoms are persistent, when ANA or anti-Ro/SSA are positive in the setting of fatigue or arthralgia, when there is unexplained hypergammaglobulinemia, parotid swelling, palpable purpura, peripheral neuropathy, abnormal urinalysis, or unexplained cytopenias, and whenever lymphoma is suspected. Ophthalmology evaluates and manages keratoconjunctivitis sicca; a Sjogren-experienced dentist or oral medicine specialist coordinates caries prevention and oral hygiene. Pulmonology, nephrology, and neurology are consulted as organ patterns dictate.
Find specialists →Sjogren syndrome is a chronic disease with a slowly progressive natural history rather than discrete recovery episodes. Sicca therapy produces symptomatic improvement within days to weeks of starting artificial tears, punctal plugs, and oral muscarinic agonists. Hydroxychloroquine reaches steady-state effect at 3-6 months. Inflammatory arthritis responds to methotrexate within 8-12 weeks. Rituximab-induced B-cell depletion lasts 6-9 months, with response in systemic features evident at 12-24 weeks. Cryoglobulinemic vasculitis often responds within 2-4 weeks of rituximab and steroids. Cutaneous lesions improve over 4-12 weeks with targeted therapy.
Regular low-to-moderate intensity exercise (walking, swimming, cycling, yoga) for 150 minutes weekly improves fatigue, mood, cardiovascular risk, and bone health. Resistance training twice weekly supports muscle mass during steroid courses. Hydrate before, during, and after exercise to compensate for reduced saliva-driven thermoregulation. During active flares, scale back to gentle range-of-motion work until inflammation settles, and avoid high-intensity outdoor exercise during peak ultraviolet hours when cutaneous photosensitivity is active.
Look for board certification in rheumatology, familiarity with the 2016 ACR/EULAR classification criteria and the 2020 EULAR management recommendations, and routine use of ESSDAI scoring at follow-up. Ask whether the practice has established referral pathways to a Sjogren-trained ophthalmologist, an oral medicine specialist, and a hematologist for lymphoma screening when indicated. Continuity of care matters for a slowly progressive disease followed across decades.
Medically reviewed by AIHealz Medical Editorial Board · May 12, 2026
Ranked by patient outcomes and specialized experience.
Specialists who treat Sjogren Syndrome. Get expert guidance and personalized care.